Want to see CH:COPN full AI Analyst Report?
COPN Stock Chart & Stats
CHF97.80
-CHF3.50(-5.38%)
At close: 4:00 PM EST
CHF97.80
-CHF3.50(-5.38%)
Day’s Range― - ―
52-Week RangeCHF53.40 - CHF129.40
Previous CloseN/A
Volume25.75K
Average Volume (3M)19.52K
Market Cap
CHF1.15B
Enterprise ValueCHF1.25B
Total Cash (Recent Filing)CHF122.66M
Total Debt (Recent Filing)CHF4.26M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Jul 23, 2026Next Dividend Ex-DateN/A
Dividend Yield1.82%
Share Statistics
EPS (TTM)-0.23
Shares Outstanding17,543,522
10 Day Avg. Volume18,700
30 Day Avg. Volume19,520
Financial Highlights & Ratios
PEG Ratio4.78
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF145.00Price Target Upside48.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.1
Revenue Forecast (FY)CHF106.30M
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Minimal LeverageVery low debt and substantial equity give the company durable financial flexibility to fund development, absorb operational swings, and support partner-funded programs. Over the next 2–6 months this reduces refinancing risk and preserves capacity to pursue strategic licensing or clinical activities despite cyclical revenue.
Diversified Revenue Model: Product Sales + LicensingA business model combining direct product sales with licensing/partner deals provides both recurring commercial revenue and non-dilutive upside from upfronts, milestones and royalties. Structurally, partner-funded development and royalties can lower required capital and broaden market reach over multiple quarters.
Demonstrated Ability To Generate High Margins & Cash In Good YearsThe company has shown it can scale profitable sales and convert them into strong operating and free cash flow when commercial conditions align. This indicates underlying product/market economics that can deliver durable returns in favorable cycles, offering a blueprint for restoring profitability when revenue stabilizes.
Bears Say
Sharp 2025 Revenue & Profit DeclineA large, rapid decline in top-line and a swing to negative margins signal weak near-term commercial momentum or loss of one-off revenue. Such a structural drop reduces operating leverage, constrains reinvestment in commercialization and R&D, and undermines visibility for sustaining medium-term growth.
Negative Operating And Free Cash Flow In 2025A move to cash burn after prior strong inflows materially weakens internal funding capacity. Even with a conservative balance sheet, sustained negative operating and free cash flow forces reliance on reserves, partner funding or external financing, which can constrain strategic choices and slow product investments over the next several quarters.
High Historical Earnings Volatility And InconsistencyA track record of boom-and-bust earnings reduces predictability of cash generation and complicates long-term planning. For a specialty pharma reliant on milestone receipts and partner commercialization, this volatility raises execution risk and makes sustaining consistent growth or securing long-term partnerships more difficult.
COSMO Pharmaceuticals N.V. News
COPN FAQ
What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?
COSMO Pharmaceuticals N.V. lowest stock price was CHF53.40 and its highest was CHF129.40 in the past 12 months.
What is COSMO Pharmaceuticals N.V.’s market cap?
COSMO Pharmaceuticals N.V.’s market cap is CHF1.15B.
When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?
COSMO Pharmaceuticals N.V.’s upcoming earnings report date is Jul 23, 2026 which is in 19 days.
How were COSMO Pharmaceuticals N.V.’s earnings last quarter?
COSMO Pharmaceuticals N.V. released its earnings results on Mar 09, 2026. The company reported -CHF0.092 earnings per share for the quarter, missing the consensus estimate of CHF0.185 by -CHF0.277.
Is COSMO Pharmaceuticals N.V. overvalued?
According to Wall Street analysts COSMO Pharmaceuticals N.V.’s price is currently Undervalued.
Does COSMO Pharmaceuticals N.V. pay dividends?
COSMO Pharmaceuticals N.V. pays a Annually dividend of CHF1.928 which represents an annual dividend yield of 1.82%. See more information on COSMO Pharmaceuticals N.V. dividends here
What is COSMO Pharmaceuticals N.V.’s EPS estimate?
COSMO Pharmaceuticals N.V.’s EPS estimate is 0.
How many shares outstanding does COSMO Pharmaceuticals N.V. have?
COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.
What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?
COSMO Pharmaceuticals N.V. reported an EPS of -CHF0.092 in its last earnings report, missing expectations of CHF0.185. Following the earnings report the stock price went down -10.522%.
Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?
Currently, no hedge funds are holding shares in CH:COPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
COPN Stock 12 Month Forecast
Average Price Target
CHF145.00
▲(48.26% Upside)
Technical Analysis
Options Prices
Currently, No data available
---